The 'forgotten' bile acid sequestrants: is now a good time to remember?
The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Over 30 years ago, bile acid sequestrants (BAS) were among the first drugs approved to lower cholesterol levels. For over 10 years, BAS have been known to reduce glucose levels. Most importantly, BAS have been shown in outcomes studies to reduce cardiovascular events. Because they are true nonsystemic agents, BAS are generally safe and not associated with serious systemic adverse experiences. Despite their proven atherosclerotic coronary heart disease (CHD) benefits, and irrespective of their favorable effects on major CHD risk factors (hypercholesterolemia and hyperglycemia), BAS are not among the more frequently used drug treatments for hypercholesterolemia, even in patients with type 2 diabetes mellitus. Recent "high-profile" findings of investigational and approved lipid-altering and antidiabetes drug therapies illustrate that drug-induced improvements in lipid and glucose levels do not always reduce CHD risk. It may therefore be time to reconsider the clinical use of BAS. This review focuses on the recent lessons learned, and the potential mechanisms involved in efficacy and safety issues raised with torcetrapib and rosiglitazone with analogies related to the use of BAS therapy. Known and proposed mechanisms of how BAS may improve lipid and glucose levels are discussed, which are effects that may help explain how BAS reduce CHD risk. Improved tolerability of newer BAS (eg, colesevelam hydrochloride) and a "new" appreciation of the historic benefits of these "old" therapeutic agents may lead to an increased treatment role for these drugs, particularly in hypercholesterolemic patients with type 2 diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the first hypercholesterolemia drugs were poorly tolerated or had adverse side effects”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [211]
In the citing paper
“today, more effective and well-tolerated drugs are available [[209], [210], [211]].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [211]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 2×
“027), and subgroup analyses have also suggested beneficial effects for pioglitazone.(29,30) But the findings of this trial were not necessarily applicable to rosiglitazone, particularly given that pioglitazone and rosiglitazone had differing effects on lipoprotein parameters.”
BackgroundResultGoodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Stamler, J. (1986) · JAMA · doi:10.1001/jama.1986.03380200061022 · Cited by 1,318 · cited 1×
“Importantly, the CHD risk was increasedwith cholesterol levels 182 to 202 mg/dL compared with less than or equal to 181 mg/dL, suggesting that no ‘‘threshold’’ existed in the relationship of CHD to total cholesterol levels as low as 181 mg/dL.(40) It was thought that the increasing risk of CHD in many populations was…”
BackgroundJones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067 · cited 1×
“Perhaps the most important events that limited BAS use was the 1987 approval of lovastatin (a ‘‘statin’’) as the first 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and the subsequent approval of other statins.(69) As a result of a wealth of subsequent data concerning lipid efficacy, CHD risk reduction ef…”
BackgroundEFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE
Hjermann, I., Holme, I., Byre, K. V., & Leren, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91338-6 · Cited by 1,033
(1970) · PubMed · Cited by 976
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966 · cited 1×
“6-mmHg increase in systolic blood pressure found with torcetrapib/ atorvastatin.(12) In a 1-year study of 850 patients with heterozygous familial hypercholesterolemia, torcetrapib/atorvastatin demonstrated large increases in HDLC and decreases in LDL-C and triglyceride (TG) levels compared with atorvastatin alone but…”
BackgroundActivation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953
Farnesoid X receptor is essential for normal glucose homeostasis
Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 882
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843
Kane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Katsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · cited 1×
“By binding bile acids, BAS may increase CCK release(111,112) and stimulate insulin secretion, possibly by increasing pancreatic beta cell sensitivity to glucose(113) Bile acids may increase incretin release such as glucagon-like peptide-1, which would be expected to lower glucose levels.(114) Although BAS upregulate C…”
BackgroundEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761 · cited 1×
“’’(32) An interim analysis from RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes), a large openlabel cardiovascular outcome study of 4447 patients with T2DM comparing rosiglitazone plus either metformin or sulfonylurea, versus the combination of metformin and sulfonylurea, d…”
BackgroundHolt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K. F., Donahee, M., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., et al. (2003) · Genes & Development · doi:10.1101/gad.1083503 · Cited by 696
Brensike, J. F., Levy, R. I., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., & Moriarty, D. J. (1984) · Circulation · doi:10.1161/01.cir.69.2.313 · Cited by 668
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Liver X Receptor Signaling Pathways in Cardiovascular Disease
Tontonoz, P., & Mangelsdorf, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0061 · Cited by 633
Cholesterol and Mortality: 30 Years of Follow-up From the Framingham Study
Anderson, K. M. (1987) · JAMA · doi:10.1001/jama.1987.03390160062027 · Cited by 620 · cited 1×
“Epidemiologic reports such as the Framingham Study, which was initiated in 1948, and which included over 10,000 men and women 30 to 65 years of age followed longitudinally over three generations, observed that CHD risk was increased by increasing LDL-C and decreasing HDL-C levels.(39) Similarly, the Multiple Risk Fact…”
MethodFu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M., Williams, P. M., Soriano, R., Corpuz, R., Moffat, B., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1671 · Cited by 579 · cited 1×
“FGF19 increases metabolic rate, decreases body weight, and improves glucose homeostasis.(129,130) Thus, a decrease in FGF19 with BAS would be expected to increase glucose levels”
BackgroundThe Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J.-C., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 552
KATO, H., TILLOTSON, J., NICHAMAN, M. Z., RHOADS, G. G., & HAMILTON, H. B. (1973) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a121518 · Cited by 542
The nuclear receptor LXR is a glucose sensor
Mitro, N., Mak, P. A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A., & Saez, E. (2007) · Nature · doi:10.1038/nature05449 · Cited by 524
Laffitte, B. A., Chao, L. C., Li, J., Walczak, R., Hummasti, S., Joseph, S. B., Castrillo, A., Wilpitz, D. C., Mangelsdorf, D. J., Collins, J. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830671100 · Cited by 502
EFFECT OF CHOLESTEROL-LOWERING DIET ON MORTALITY FROM CORONARY HEART-DISEASE AND OTHER CAUSES
Miettinen, M., Karvonen, M., Turpeinen, O., Elosuo, R., & Paavilainen, E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92208-8 · Cited by 497
Diet, Lipoproteins, and the Progression of Coronary Atherosclerosis: The Leiden Intervention Trial
Arntzenius, A. C., Kromhout, D., Barth, J. D., Reiber, J. H. C., Bruschke, A. V. G., Buis, B., van Gent, C. M., Kempen-Voogd, N., Strikwerda, S., & van der Velde, E. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121301 · Cited by 497
Gagné, C., Bays, H. E., Weiss, S. R., Mata, P., Quinto, K., Melino, M., Cho, M., Musliner, T. A., & Gumbiner, B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02774-1 · Cited by 495
Self-citationBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up
Cashin-Hemphill, L. (1990) · JAMA · doi:10.1001/jama.264.23.3013 · Cited by 493
Wilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke · doi:10.1161/01.str.0000257974.06317.49 · Cited by 475
Stoffel, M., & Duncan, S. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13209 · Cited by 406 · cited 2×
“A nonsense mutation of the HNF4a gene is responsible for an autosomal-dominant form of subtype 1 maturity-onset diabetes of the young (gene named MODY1).(4,115) HNF4a is a member of the steroid/thyroid receptor superfamily of transcription factors that regulates genes essential for normal liver, gut, kidney, and pancr…”
BackgroundLUNDÅSEN, T., GÄLMAN, C., ANGELIN, B., & RUDLING, M. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01731.x · Cited by 405 · cited 1×
“Bile acids increase, and BAS decrease FGF19 activity.(128) FGF19 increases metabolic rate, decreases body weight, and improves glucose homeostasis.”
BackgroundClark, R. W., Sutfin, T. A., Ruggeri, R. B., Willauer, A. T., Sugarman, E. D., Magnus-Aryitey, G., Cosgrove, P. G., Sand, T. M., Wester, R. T., Williams, J. A., et al. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000118278.21719.17 · Cited by 371 · cited 1×
“High-dose torcetrapib monotherapy (240 mg) dramatically increased high-density lipoprotein cholesterol (HDL-C) greater than 100%(8) and decreased low-density lipoprotein cholesterol (LDL-C) levels greater than 40%.(9) Even at the lower torcetrapib dose used in the large cardiovascular (1)Louisville Metabolic and Ather…”
BackgroundYamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., & Fukamizu, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314322200 · Cited by 364
Kerr, T. A., Saeki, S., Schneider, M., Schaefer, K., Berdy, S., Redder, T., Shan, B., Russell, D. W., & Schwarz, M. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00154-5 · Cited by 351
Cholesterol lowering trials in coronary heart disease: Frequency of citation and outcome.
Ravnskov, U. (1992) · BMJ · doi:10.1136/bmj.305.6844.15 · Cited by 313 · cited 1×
“Another factor that contributed to the limited use of lipid-altering drugs to reduce CHD risk was that even after the LRC-CPPT, not everyone fully believed the cholesterol hypothesis, a skepticism extending into the early 1990s.(46) It was then that another landmark trial, the Scandinavian Simvastatin Survival Study (…”
BackgroundEmployer's liability for cancer of the scrotum
(1968) · The Lancet · doi:10.1016/s0140-6736(68)92497-5 · Cited by 308
Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis
Cao, G., Liang, Y., Broderick, C. L., Oldham, B. A., Beyer, T. P., Schmidt, R. J., Zhang, Y., Stayrook, K. R., Suen, C., Otto, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210208200 · Cited by 299
Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor
Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J., Cook, T., Christe, M. E., Michael, L. F., & Burris, T. P. (2005) · Endocrinology · doi:10.1210/en.2004-0965 · Cited by 288
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · cited 1×
“Specifically, it is the lower LDL-C treatment targets among patients at highest CHD risk(73) (such as T2DM) that significantly explain why patients at the most risk for CHD are often the same patients who are the least likely to achieve their LDLC treatment goals.(74,75) In other words, given lower LDL-C treatment tar…”
BackgroundStatin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Self-citationSeo, J. B., Moon, H. M., Kim, W. S., Lee, Y. S., Jeong, H. W., Yoo, E. J., Ham, J., Kang, H., Park, M.-G., Steffensen, K. R., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3430-3444.2004 · Cited by 250
Transcriptional Regulation of the Human Sterol 12α-Hydroxylase Gene (CYP8B1)
Zhang, M., & Chiang, J. Y. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105117200 · Cited by 247
Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R., & Bailey, W. L. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.003 · Cited by 221
Robertson, T. L., Kato, H., Gordon, T., Kagan, A., Rhoads, G. G., Land, C. E., Worth, R. M., Belsky, J. L., Dock, D. S., Miyanishi, M., et al. (1977) · The American Journal of Cardiology · doi:10.1016/s0002-9149(77)80198-7 · Cited by 221 · cited 1×
“Emigration studies of Japanese men living outside of Japan (such as in Hawaii and San Francisco) revealed higher cholesterol levels and a higher CHD risk.(37) Population studies from 16 different locations in seven countries reported that the highest rate of CHD deaths occurred in locations with the highest cholestero…”
BackgroundDe Fabiani, E., Mitro, N., Gilardi, F., Caruso, D., Galli, G., & Crestani, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305079200 · Cited by 210
Brendel, C., Schoonjans, K., Botrugno, O. A., Treuter, E., & Auwerx, J. (2002) · Molecular Endocrinology · doi:10.1210/me.2001-0194 · Cited by 201
Garg, A., & Grundy, S. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-6-199409150-00004 · Cited by 187
Bays, H. E., Ose, L., Fraser, N., Tribble, D. L., Quinto, K., Reyes, R., Johnson-Levonas, A. O., Sapre, A., & Donahue, S. R. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.016 · Cited by 179
Self-citationRosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 178
Bile???Acid???Sequestrants???and???the???Treatment of Type??2??Diabetes??Mellitus
Staels, B., & Kuipers, F. (2007) · Drugs · doi:10.2165/00003495-200767100-00001 · Cited by 176
Pharmacotherapy for dyslipidaemia – current therapies and future agents
Bays, H., & Stein, E. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1901 · Cited by 172
Self-citationFXR: a promising target for the metabolic syndrome?
Cariou, B., & Staels, B. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.03.002 · Cited by 168
Coronary heart disease in seven countries
Keys, A. (1997) · Nutrition · doi:10.1016/s0899-9007(96)00410-8 · Cited by 154 · cited 1×
“Population studies from 16 different locations in seven countries reported that the highest rate of CHD deaths occurred in locations with the highest cholesterol levels.(38) Epidemiologic reports such as the Framingham Study, which was initiated in 1948, and which included over 10,000 men and women 30 to 65 years of a…”
BackgroundBays, H. E., Dujovne, C. A., McGovern, M. E., White, T. E., Kashyap, M. L., Hutcheson, A. G., & Crouse, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00007-9 · Cited by 154
Self-citationRapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
Hetzel, J., Balletshofer, B. M., Rittig, K., Walcher, D., Kratzer, W., Hombach, V., Häring, H., Köenig, W., & Marx, N. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000176192.16951.9a · Cited by 148
LXRα is the dominant regulator of CYP7A1 transcription
Gupta, S., Pandak, W. M., & Hylemon, P. B. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00229-2 · Cited by 147
McKenney, J. M., Davidson, M. H., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.066 · Cited by 144 · cited 1×
“outcomes trials, early studies reported that 60 mg torcetrapib added to stable atorvastatin therapy in hypercholesterolemic patients resulted in a further 33% increase in HDL-C and a 16% further decrease in LDL-C levels.(7,10) This supported the hypothesis that combining a cholesteryl ester transfer protein inhibitor…”
ResultEffect of cholestyramine on bile acid metabolism in normal man
Garbutt, J. T., & Kenney, T. J. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107100 · Cited by 138 · cited 1×
“Chenodeoxycholic acid (dihydroxy bile salt), ursodeoxycholic acid (monohydroxy bile salt), and cholestyramine-supplemented diets may all decrease intestinal glucose uptake(106,107) BAS alter the bile acid composition in the enterohepatic circulation to predominantly glycine-conjugated trihydroxy bile acids (cholic aci…”
BackgroundPleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity
Giannini, S., Serio, M., & Galli, A. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347546 · Cited by 137
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4α
Inoue, Y., Yu, A.-M., Yim, S. H., Ma, X., Krausz, K. W., Inoue, J., Xiang, C. C., Brownstein, M. J., Eggertsen, G., Björkhem, I., et al. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500430-jlr200 · Cited by 135
Efanov, A. M., Sewing, S., Bokvist, K., & Gromada, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s75 · Cited by 135
Samaha, F. F., Szapary, P. O., Iqbal, N., Williams, M. M., Bloedon, L. T., Kochar, A., Wolfe, M. L., & Rader, D. J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000200136.56716.30 · Cited by 130
CETP Inhibitors to Increase HDL Cholesterol Levels
Tall, A. R. (2007) · New England Journal of Medicine · doi:10.1056/nejme078029 · Cited by 129 · cited 1×
“However, ILLUMINATE was prematurely discontinued because torcetrapib/atorvastatin therapy was found to have increased death, myocardial infarctions, angina, revascularization procedures, and heart failure compared with atorvastatin alone.(11) The independent, parallel study called ILLUSTRATE (Investigation of Lipid Le…”
ResultLiver X Receptors Downregulate 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity
Stulnig, T. M., Oppermann, U., Steffensen, K. R., Schuster, G. U., & Gustafsson, J.-A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2426 · Cited by 115
Regulation of the release of cholecystokinin by bile salts in dogs and humans
Gomez, G. A., Upp, J. R., Lluı́s, F., Alexander, R. W., Poston, G. J., Greeley, G. H., & Thompson, J. C. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90564-1 · Cited by 110
Adiposopathy: Sick Fat Causes High Blood Sugar, High Blood Pressure and Dyslipidemia
Bays, H., Abate, N., & Chandalia, M. (2005) · Future Cardiology · doi:10.1517/14796678.1.1.39 · Cited by 105
Self-citationBays, H., Blonde, L., & Rosenson, R. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.6.871 · Cited by 103
Self-citationBays, H., Davidson, M., Jones, M. R., & Abby, S. L. (2006) · American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.039 · Cited by 103
Self-citationColesevelam HCl: a non-systemic lipidaltering drug
Bays, H., & Dujovne, C. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.779 · Cited by 98 · cited 6×
“The increase in cholesterol catabolism to bile acids results in a compensatory increase in hepatic LDL receptor activity, clearing LDL-C from the circulation and thus reduces LDL-C levels.(48) Improvement in peripheral cholesterol transport may be another lipid benefit of BAS.”
BackgroundResultInfluentialSelf-citationPrevention of coronary heart disease and other complications of atherosclerosis by modified diet
Dayton, S., & Pearce, M. L. (1969) · The American Journal of Medicine · doi:10.1016/0002-9343(69)90026-6 · Cited by 82
Levi, Z., Shaish, A., Yacov, N., Levkovitz, H., Trestman, S., Gerber, Y., Cohen, H. W., Dvir, A., Rhachmani, R., Ravid, M., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00240.x · Cited by 78
Adiposopathy: why do adiposity and obesity cause metabolic disease?
Bays, H., & Ballantyne, C. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.389 · Cited by 74
Self-citationYAMAKAWA, T., TAKANO, T., UTSUNOMIYA, H., KADONOSONO, K., & OKAMURA, A. (2007) · Endocrine Journal · doi:10.1507/endocrj.k05-098 · Cited by 71
Hodis, H. N., Mack, W. J., Zheng, L., Li, Y., Torres, M., Sevilla, D., Stewart, Y., Hollen, B., Garcia, K., Alaupovic, P., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2462 · Cited by 60
Lipid-lowering effects of colesevelam HCl in combination with ezetimibe
Bays, H., Rhyne, J., Abby, S., Lai, Y.-L., & Jones, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148436 · Cited by 58
Self-citationDifferences between clinical trial efficacy and real-world effectiveness.
Davidson, M. H. (2006) · PubMed · Cited by 57
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone
Bays, H. E., & Dujovne, C. A. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0052-6 · Cited by 55
Self-citationRoberts, A. W., Thomas, A., Rees, A., & Evans, M. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200312000-00004 · Cited by 52
Farnesoid X Receptor: A New Player in Glucose Metabolism?
Cariou, B., Durán-Sandoval, D., Kuipers, F., & Staels, B. (2005) · Endocrinology · doi:10.1210/en.2004-1595 · Cited by 43
Stimulation of Pancreatic Secretion and Growth in the Rat After Feeding Cholestyramine
Brand, S. J., & Morgan, R. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80016-4 · Cited by 40 · cited 1×
“BAS may increase pancreatic insulin secretion.(109) Cholecystokinin (CCK) is sometimes described as an incretin, and its release is inhibited by bile acids.”
BackgroundSuzuki, T., Oba, K., Futami‐Suda, S., Suzuki, K., Ouchi, M., Igari, Y., Matsumura, N., Watanabe, K., Kigawa, Y., & Nakano, H. (2006) · Journal of Nippon Medical School · doi:10.1272/jnms.73.277 · Cited by 38
Bays, H. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.393 · Cited by 37
Self-citationDonovan, J. M., von Bergmann, K., Setchell, K. D. R., Isaacsohn, J., Pappu, A. S., Illingworth, D. R., Olson, T., & Burke, S. K. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2765-8 · Cited by 35 · cited 1×
“Thus, although the HDL-C-raising effects of BAS are modest, what may be of more clinical importance is the degree by which BAS improve this HDL flux, which is supported by increased fecal cholesterol excretion found with colesevelam HCl administration(49) (although other studies suggest no increase in neutral sterol e…”
ResultBays, H. E., & Cohen, D. E. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210525 · Cited by 33
Self-citationThe vascular biology of peroxisome proliferator-activated receptors: Modulation of atherosclerosis
Verma, S., & Szmitko, P. E. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70981-3 · Cited by 31
Role of endogenous bile on basal and postprandial CCK release in humans
Koide, M., Okabayashi, Y., & Otsuki, M. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01296080 · Cited by 30 · cited 1×
“Cholecystokinin (CCK) is sometimes described as an incretin, and its release is inhibited by bile acids.(110) By binding bile acids, BAS may increase CCK release(111,112) and stimulate insulin secretion, possibly by increasing pancreatic beta cell sensitivity to glucose(113) Bile acids may increase incretin release su…”
BackgroundShibata, S., Hayakawa, K., Egashira, Y., & Sanada, H. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.10.003 · Cited by 28
Torcetrapib/atorvastatin combination therapy
Bays, H. E., McKenney, J. M., & Davidson, M. H. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.5.789 · Cited by 28 · cited 3×
“dollars for Phase III development alone).(7) High-dose torcetrapib monotherapy (240 mg) dramatically increased high-density lipoprotein cholesterol (HDL-C) greater than 100%(8) and decreased low-density lipoprotein cholesterol (LDL-C) levels greater than 40%.”
BackgroundMethodResultSelf-citationInfluence of cholestyramine on synthesis of cholesterol and bile acids in germfree rats.
Gustafsson, B. E., Angelin, B., Einarsson, K., & Gustafsson, J.-Α. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40680-7 · Cited by 25
Modulation of Metabolic Syndrome by Fibroblast Growth Factor 19 (FGF19)?
Strack, A. M., & Myers, R. W. (2004) · Endocrinology · doi:10.1210/en.2004-0367 · Cited by 25
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol
Bays, H. E. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02971-5 · Cited by 23 · cited 1×
“BAS potentially increase the gene expression of apoprotein A1, lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein, scavenger receptor B1, and the liver X receptor (LXR),(49) all important for the HDL-mediated ‘‘flux’’ of cholesterol from peripheral tissues such as arterial macrophages(7) to the l…”
BackgroundSelf-citationEffect of cholestyramine on bile acid metabolism in conventional rats
Imai, Y., Kawata, S., Inada, M., Miyoshi, S., Minami, Y., Matsuzawa, Y., Uchida, K., & Tarui, S. (1987) · Lipids · doi:10.1007/bf02540367 · Cited by 22 · cited 1×
“BAS decrease total bile acid secretion, but increase the chenodeoxycholic acid composition of the bile acids that are secreted.(104,105) Chenodeoxycholic acid (dihydroxy bile salt), ursodeoxycholic acid (monohydroxy bile salt), and cholestyramine-supplemented diets may all decrease intestinal glucose uptake(106,107) B…”
BackgroundThomson, A. B. R., & Keelan, M. (2009) · Digestion · doi:10.1159/000199586 · Cited by 22
Extended-release niacin/lovastatin: the first combination product for dyslipidemia
Bays, H. E. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.4.485 · Cited by 21
Self-citationThiazolidinediones: Beyond Glycemic Control
Reynolds, K., & Goldberg, R. B. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605010-00004 · Cited by 21
Self-citationColestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients
Date, T. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg1023 · Cited by 21
Kogire, M., Gomez, G. A., Uchida, T., Ishizuka, J., Greeley, G. H., & Thompson, J. C. (1992) · Pancreas · doi:10.1097/00006676-199201000-00003 · Cited by 20
PROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation
Skyler, J. S. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.2.63 · Cited by 20 · cited 1×
“Pioglitazone did not reach primary end point efficacy, which included all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndrome, endovascular or surgical intervention in the coronary or leg arteries, and amputation above the ankle.(28,29) But the secondary end point of all-cause mortality, n…”
BackgroundCardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues
Caulfield, M. T., & O’Brien, K. D. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.2.81 · Cited by 19 · cited 1×
“Subsequent analysis suggested that if such an effect existed, it may be specific to certain agents such as tolbutamide rather than to the entire sulfonylurea class.(15) Furthermore, even if improvement in glucose levels with the newer sulfonylureas did not reduce macrovascular disease, it was concluded by some that ‘‘…”
BackgroundPilot Study to Reduce Dioxins in the Human Body
Sakurai, K., Todaka, E., Saitō, Y., & Mori, C. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.792 · Cited by 18
Colestimide Reduces Blood Polychlorinated Biphenyl (PCB) Levels
Sakurai, K., Fukata, H., Todaka, E., Saitō, Y., Bujo, H., & Mori, C. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1478 · Cited by 16
Kirk, J. K., Huber, K. R., & Clinch, C. R. (2005) · North Carolina Medical Journal · doi:10.18043/ncm.66.6.415 · Cited by 15
Kawashiri, M., Higashikata, T., Nohara, A., Kobayashi, J., Inazu, A., Koizumi, J., & Mabuchi, H. (2005) · Circulation Journal · doi:10.1253/circj.69.515 · Cited by 15
Läutamaki, R., Nuutila, P., Airaksinen, J. K. E., Leino, A. E., Hiekkanen, H., Turiceanu, M., Stewart, M. W., Knuuti, J. M., & Rönnemaa, T. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.31 · Cited by 14
Reduction of dioxins and polychlorinated biphenyls (PCBs) in human body.
Mochida, Y., Fukata, H., Matsuno, Y., & Mori, C. (2007) · PubMed · doi:10.15017/4282 · Cited by 12
Hypocholesterolemic activity of colestipol in diabetes.
Ms, B., & Br, B. (1975) · PubMed · Cited by 12
Hypertriglyceridemia and Coronary Heart Disease
Jones, J. D. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.189 · Cited by 11 · cited 1×
“It is not known if elevated TG levels are simply a marker for underlying dysmetabolisms that increase CHD risk or whether elevated TG themselves are an independent CHD risk factor.(68) Furthermore, no prospective outcomes trial involving a Table 5.”
BackgroundRole of Cholecystokinin in Cholestyramine-induced Changes of the Exocrine Pancreas
Koop, I., Lindenthal, M., Schade, M., TRAUTMANN, M. E., Adler, G., & Arnold, R. (1991) · Pancreas · doi:10.1097/00006676-199109000-00010 · Cited by 11
Suzuki, T., Oba, K., Futami‐Suda, S., Suzuki, K., Ouchi, M., Igari, Y., Matsumura, N., Watanabe, K., Kigawa, Y., & Nakano, H. (2007) · Journal of Nippon Medical School · doi:10.1272/jnms.74.81 · Cited by 11
Davidson, M. H., Dittakavi, V., Bandari, A., Davidson, D., Maki, K. C., & Subbaiah, P. V. (2006) · Journal of Applied Research · Cited by 10
Inhibition of ileal bile acid absorption by colestimide
TAKEUCHI, A., Sano, N., & Takikawa, H. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03005.x · Cited by 8
[Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits].
Wang, Z., Luo, F., & Liu, X. (2005) · PubMed · Cited by 8
Rosiglitazone approved for treatment of type 2 diabetes
Miller, J. L. (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.13.1292 · Cited by 8 · cited 5×
“26 However, rosiglitazone increased LDL-C levels with the clinical implications being unclear, given that rosiglitazone increased the concentration of large (buoyant) LDL particles and not the small, dense LDL particles, with the later being the more atherogenic particles, and the more typical LDL pattern found in pat…”
BackgroundInfluentialTasaki, H., Miyamoto, M., Kubara, T., Kamezaki, F., Tanaka, S., Yamashita, K., Tsutsui, M., & Nakashima, Y. (2005) · Circulation Journal · doi:10.1253/circj.70.14 · Cited by 7
[Colestipol by hypercholesteremia in diabetics].
Düntsch, G. (1977) · PubMed · Cited by 6
Conjugated dihydroxy bile salt inhibition of glucose influx in rat jejunumin vitro
FELDMAN, E. B., Watt, R., & Feldman, D. S. (1977) · Digestive Diseases and Sciences · doi:10.1007/bf01071888 · Cited by 6
What are the long-term effects of statin therapy?
Bays, H. E. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0478 · Cited by 5
Self-citation[Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice].
Zhao, Q., Yan, D., Song, A.-L., Wang, W., Shi, Q. S., Wang, L., Chen, D., Fang, W., Wu, Y., Xu, J., et al. (2005) · PubMed · Cited by 1
Research works printed but not linked: 4
- 1998, 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS Group., Lancet, 352, 837
- 1994, 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S., Lancet, 344, 1383
- Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice., Proc Natl Acad Sci USA, 103, 1006, 10.1073/pnas.0506982103 · DOI · Paper page
- Bays, 2006, Adiposopathy is a more rational treatment target for metabolic disease than obesity alone., Curr Atheroscler Rep, 8, 144, 10.1007/s11883-006-0052-6 · DOI
Cited by
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
Dawson, P. A. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_4 · Cited by 227
“…and mortality from cardiovascular disease associated with ileal resection in the POSCH study (Program on the Surgical Control of Hyperlipidemias) (Buchwald et al. 1990) or from the use of polymeric bile acid sequestrants, such as cholestyramine, or colestipol (1984; Bays and Goldberg 2007).”
BackgroundBays, H., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Self-citationMancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., & Pope, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 188
“Ezetimibe acts by directly inhibiting the cholesterol transporter Niemann Pick C 1-like 1 (NPC1L1) located primarily in brush border of the proximal small bowel.199 It significantly reduces absorption of both dietary and biliary cholesterol resulting in lower LDL-C.”
BackgroundInfluentialLiver disease associated with canalicular transport defects: Current and future therapies
Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. J., & Houwen, R. H. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.012 · Cited by 179
“Given the potentially better tolerability and higher efficacy of the new bile salt resin binders with other polymer structures, suchascolesevalam[127], thesedrugsshouldbe thetopic of further investigations.”
Background
Metadata
- Authors
- Bays, H. E., & Goldberg, R. B.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- University of Miami (US)
- Corresponding author
- Bays, Harold E
- Venue
- American Journal of Therapeutics
- Published
- 2007-11
- Volume
- 14
- Issue
- 6
- Pages
- 567-580
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2037964248
- Cited by
- 83
- References
- 134
- Citations by year
- 2025: 1 · 2023: 4 · 2022: 4 · 2021: 1 · 2017: 1 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 7
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- bile acid sequestrants, hypercholesterolemia, type 2 diabetes, coronary heart disease risk, blood glucose reduction, cholesterol lowering, torcetrapib, rosiglitazone, colesevelam, drug safety, lipid-lowering therapy, glucose-lowering therapy
- MeSH terms
- Liver X Receptors, Anticholesteremic Agents, Bile Acids and Salts, Blood Glucose, Cholestyramine Resin, Clinical Trials as Topic, Colestipol, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Humans, Lipids, Receptors, Cytoplasmic and Nuclear, Dyslipidemias, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.